Sandoz introduces rivastigmine patch

PRINCETON, N.J. — Sandoz on Wednesday introduced rivastigmine transdermal system, a generic version of Exelon Patch1, in the United States.

The rivastigmine patch is used to treat mild, moderate and severe memory problems associated with both Alzheimer’s disease and Parkinson’s disease.

"Sandoz is pleased to make rivastigmine patch available as a generic option for patients with memory problems associated with Alzheimer’s disease,” Sandoz president Peter Goldschmidt said. “Rivastigmine has been studied for more than a decade in clinical trials and is the only Alzheimer's disease treatment that comes in the form of a patch with the medication absorbed through the skin.”

For the 12 months ending in June, U.S. sales for the rivastigmine patch were $646 million, according to the company. Sandoz will sell rivastigmine in 13.3 mg strength, the same strength as the brand.